Effect of transcatheter arterial chemoembolization combined with sorafenib in hepatocellular carcinoma patients in middle or advanced stage and nursing measures

Objective To explore the effect and nursing measures of transcatheter arterial chemoembolization(TACE)combined with sorafenib in the treatment of hepatocellular carcinoma patients in middle or advanced stage. Methods The clinical data of 60 patients with advanced HCC treated by TACE and sorafenib were analyzed retrospectively. According to the random number table method, the patients were divided into control group and observation group, with 30 cases in each group. The control group received routine nursing, while the observation group received predictive nursing, and the incidence of toxic and side effects in the two groups was compared. The median survival time, disease progression time and mortality rate of the two groups were observed and recorded. Results There were no significant differences in median survival time, disease progression time and mortality rates between the two groups(P>0.05); the incidence of toxic and side effects(except for coagulation function disorders)in the observation group was lower than that in the control group, the difference was statistically significant(P<0.05). Conclusion TACE combined with sorafenib can significantly prolong the survival period of patients with advanced HCC, and the predictive nursing intervention can reduce the effect of toxic and side effects.